BERKELEY HEIGHTS, N.J., May 21 /PRNewswire-FirstCall/ -- Genta
Incorporated (OTC Bulletin Board: GNTA) announced that multiple abstracts
featuring its lead oncology products will be featured at the 44th annual
meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May
30 - June 3, 2008.
The abstracts include the following:
-- Initial Phase 1 Clinical and Pharmacokinetic Assessment of G4544, an
oral gallium-containing Compound. Poster # 53C Abstract No: 8592
Saturday, May 31, 2008.
-- A Phase I/II Study to Determine the Feasibility and Efficacy of the
Triple Combination of Oblimersen (OBL), Abraxane (ABX), and
Temozolomide (TMZ) in Metastatic Melanoma and Normal LDH. Poster # 16
Abstract No: 9027 Sunday, June 1, 2008.
-- Effect of the Addition of Oblimersen (Bcl-2 antisense) to
Fludarabine/Cyclophosphamide for Relapsed/Refractory Chronic
Lymphocytic Leukemia (CLL) on Survival in Patients Who Achieve CR/nPR:
Five-year Follow-up from a Randomized Phase III Study. Abstract # 7008
Monday, June 2, 2008.
-- Prognostic Impact of Baseline LDH on Survival Independent of Tumor
Burden in Advanced Melanoma: Results of Phase III Trial of
Oblimersen-Dacarbazine (OBL-DTIC) vs. DTIC. (Publication).
-- Short IV Infusion of Oblimersen (OBL) in Patients with Solid Tumors:
Safety and Pharmacokinetics. (Publication).
-- Pharmacokinetics of Albumin-bound Paclitaxel (ABX) in combination with
Temozolomide (TMZ) and Oblimersen Sodium (OBL) in Patients with
Advanced Melanoma. (Publication).
Genta Incorporated is a biopharmaceutical company with a diversified
product portfolio that is focused on delivering innovative products for the
treatment of patients with cancer. Two major programs anchor the Company's
research platform: DNA/RNA-based Medici
|SOURCE Genta Incorporated|
Copyright©2008 PR Newswire.
All rights reserved